Literature DB >> 26701664

Suppression of Proinflammatory and Prosurvival Biomarkers in Oral Cancer Patients Consuming a Black Raspberry Phytochemical-Rich Troche.

Thomas J Knobloch1, Lana K Uhrig2, Dennis K Pearl3, Bruce C Casto2, Blake M Warner4, Steven K Clinton5, Christine L Sardo-Molmenti6, Jeanette M Ferguson7, Brett T Daly8, Kenneth Riedl9, Steven J Schwartz9, Yael Vodovotz9, Anthony J Buchta10, David E Schuller11, Enver Ozer11, Amit Agrawal11, Christopher M Weghorst2.   

Abstract

Black raspberries (BRB) demonstrate potent inhibition of aerodigestive tract carcinogenesis in animal models. However, translational clinical trials evaluating the ability of BRB phytochemicals to impact molecular biomarkers in the oral mucosa remain limited. The present phase 0 study addresses a fundamental question for oral cancer food-based prevention: Do BRB phytochemicals successfully reach the targeted oral tissues and reduce proinflammatory and antiapoptotic gene expression profiles? Patients with biopsy-confirmed oral squamous cell carcinomas (OSCC) administered oral troches containing freeze-dried BRB powder from the time of enrollment to the date of curative intent surgery (13.9 ± 1.27 days). Transcriptional biomarkers were evaluated in patient-matched OSCCs and noninvolved high at-risk mucosa (HARM) for BRB-associated changes. Significant expression differences between baseline OSCC and HARM tissues were confirmed using a panel of genes commonly deregulated during oral carcinogenesis. Following BRB troche administration, the expression of prosurvival genes (AURKA, BIRC5, EGFR) and proinflammatory genes (NFKB1, PTGS2) were significantly reduced. There were no BRB-associated grade 3-4 toxicities or adverse events, and 79.2% (N = 30) of patients successfully completed the study with high levels of compliance (97.2%). The BRB phytochemicals cyanidin-3-rutinoside and cyanidin-3-xylosylrutinoside were detected in all OSCC tissues analyzed, demonstrating that bioactive components were successfully reaching targeted OSCC tissues. We confirmed that hallmark antiapoptotic and proinflammatory molecular biomarkers were overexpressed in OSCCs and that their gene expression was significantly reduced following BRB troche administration. As these molecular biomarkers are fundamental to oral carcinogenesis and are modifiable, they may represent emerging biomarkers of molecular efficacy for BRB-mediated oral cancer chemoprevention. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26701664      PMCID: PMC4764140          DOI: 10.1158/1940-6207.CAPR-15-0187

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  69 in total

Review 1.  BCL-2 family antagonists for cancer therapy.

Authors:  Guillaume Lessene; Peter E Czabotar; Peter M Colman
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

Review 2.  Alcohol consumption and cancers of the oral cavity and pharynx from 1988 to 2009: an update.

Authors:  Binh Y Goldstein; Shen-Chih Chang; Mia Hashibe; Carlo La Vecchia; Zuo-Feng Zhang
Journal:  Eur J Cancer Prev       Date:  2010-11       Impact factor: 2.497

3.  Nuclear STK15 expression is associated with aggressive behaviour of oral carcinoma cells in vivo and in vitro.

Authors:  Shou-Yen Kao; Yu-Ping Chen; Hsi-Feng Tu; Chung-Ji Liu; Ann-How Yu; Cheng-Hsien Wu; Kuo-Wei Chang
Journal:  J Pathol       Date:  2010-09       Impact factor: 7.996

4.  Diet and the risk of head and neck cancer: a pooled analysis in the INHANCE consortium.

Authors:  Shu-Chun Chuang; Mazda Jenab; Julia E Heck; Cristina Bosetti; Renato Talamini; Keitaro Matsuo; Xavier Castellsague; Silvia Franceschi; Rolando Herrero; Deborah M Winn; Carlo La Vecchia; Hal Morgenstern; Zuo-Feng Zhang; Fabio Levi; Luigino Dal Maso; Karl Kelsey; Michael D McClean; Thomas Vaughan; Philip Lazarus; Joshua Muscat; Heribert Ramroth; Chu Chen; Stephen M Schwartz; Jose Eluf-Neto; Richard B Hayes; Mark Purdue; Stefania Boccia; Gabriella Cadoni; David Zaridze; Sergio Koifman; Maria Paula Curado; Wolfgang Ahrens; Simone Benhamou; Elena Matos; Pagona Lagiou; Neonilla Szeszenia-Dabrowska; Andrew F Olshan; Leticia Fernandez; Ana Menezes; Antonio Agudo; Alexander W Daudt; Franco Merletti; Gary J Macfarlane; Kristina Kjaerheim; Dana Mates; Ivana Holcatova; Stimson Schantz; Guo-Pei Yu; Lorenzo Simonato; Hermann Brenner; Heiko Mueller; David I Conway; Peter Thomson; Eleonora Fabianova; Ariana Znaor; Peter Rudnai; Claire M Healy; Gilles Ferro; Paul Brennan; Paolo Boffetta; Mia Hashibe
Journal:  Cancer Causes Control       Date:  2011-10-29       Impact factor: 2.506

Review 5.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

Authors:  Boudewijn J M Braakhuis; Maarten P Tabor; J Alain Kummer; C René Leemans; Ruud H Brakenhoff
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

6.  Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.

Authors:  Christina I Tsien; Mukesh K Nyati; Aarif Ahsan; Susmita G Ramanand; Douglas B Chepeha; Francis P Worden; Joseph I Helman; Nisha D'Silva; Carol R Bradford; Gregory T Wolf; Theodore S Lawrence; Avraham Eisbruch
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

7.  Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.

Authors:  D M Shin; J Y Ro; W K Hong; W N Hittelman
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

8.  Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.

Authors:  Abhijit Mazumdar; Ying C Henderson; Adel K El-Naggar; Subrata Sen; Gary L Clayman
Journal:  Head Neck       Date:  2009-05       Impact factor: 3.147

9.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205

10.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

View more
  18 in total

1.  Storage conditions modulate the metabolomic profile of a black raspberry nectar with minimal impact on bioactivity.

Authors:  Matthew D Teegarden; Thomas J Knobloch; Christopher M Weghorst; Jessica L Cooperstone; Devin G Peterson
Journal:  Food Funct       Date:  2018-09-19       Impact factor: 5.396

Review 2.  An Integrated Approach for Preventing Oral Cavity and Oropharyngeal Cancers: Two Etiologies with Distinct and Shared Mechanisms of Carcinogenesis.

Authors:  Karam El-Bayoumy; Neil D Christensen; Jiafen Hu; Raphael Viscidi; Douglas B Stairs; Vonn Walter; Kun-Ming Chen; Yuan-Wan Sun; Joshua E Muscat; John P Richie
Journal:  Cancer Prev Res (Phila)       Date:  2020-05-20

3.  Modulation of the oral glucocorticoid system during black raspberry mediated oral cancer chemoprevention.

Authors:  Divya Nedungadi; Nathan Ryan; Kelvin Anderson; Felipe F Lamenza; Pete P Jordanides; Michael J Swingler; Liva Rakotondraibe; Kenneth M Riedl; Hans Iwenofu; Steve Oghumu
Journal:  Carcinogenesis       Date:  2022-02-11       Impact factor: 4.944

4.  Effects of Black Raspberry on Dibenzo[a,l]Pyrene Diol Epoxide Induced DNA Adducts, Mutagenesis, and Tumorigenesis in the Mouse Oral Cavity.

Authors:  Kun-Ming Chen; Joseph B Guttenplan; Yuan-Wan Sun; Timothy Cooper; Nora A E Shalaby; Wieslawa Kosinska; Gabrielle Benitez; Cesar Aliaga; Junjia Zhu; Jason Liao; Krishne Gowda; Shantu Amin; Gary Stoner; Karam El-Bayoumy
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-20

5.  Black Raspberry Inhibits Oral Tumors in Mice Treated with the Tobacco Smoke Constituent Dibenzo(def,p)chrysene Via Genetic and Epigenetic Alterations.

Authors:  Kun-Ming Chen; Yuan-Wan Sun; Yuka Imamura Kawasawa; Anna C Salzberg; Junjia Zhu; Krishne Gowda; Cesar Aliaga; Shantu Amin; Hannah Atkins; Karam El-Bayoumy
Journal:  Cancer Prev Res (Phila)       Date:  2020-01-22

6.  Profiling the impact of thermal processing on black raspberry phytochemicals using untargeted metabolomics.

Authors:  Matthew D Teegarden; Steven J Schwartz; Jessica L Cooperstone
Journal:  Food Chem       Date:  2018-09-11       Impact factor: 7.514

Review 7.  Protective Role of Dietary Berries in Cancer.

Authors:  Aleksandra S Kristo; Dorothy Klimis-Zacas; Angelos K Sikalidis
Journal:  Antioxidants (Basel)       Date:  2016-10-19

Review 8.  Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Authors:  Aarti Bhatia; Barbara Burtness
Journal:  Cancers (Basel)       Date:  2017-08-31       Impact factor: 6.639

9.  Inhibition of Pro-inflammatory and Anti-apoptotic Biomarkers during Experimental Oral Cancer Chemoprevention by Dietary Black Raspberries.

Authors:  Steve Oghumu; Bruce C Casto; Jennifer Ahn-Jarvis; Logan C Weghorst; Jim Maloney; Paul Geuy; Kyle Z Horvath; Claire E Bollinger; Blake M Warner; Kurt F Summersgill; Christopher M Weghorst; Thomas J Knobloch
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

10.  Black Raspberries and Protocatechuic Acid Mitigate DNFB-Induced Contact Hypersensitivity by Down-Regulating Dendritic Cell Activation and Inhibiting Mediators of Effector Responses.

Authors:  Kelvin Anderson; Nathan Ryan; Arham Siddiqui; Travis Pero; Greta Volpedo; Jessica L Cooperstone; Steve Oghumu
Journal:  Nutrients       Date:  2020-06-06       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.